{
    "clinical_study": {
        "@rank": "56937", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "CP-690,550 5 mg BID", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "CP-690,550 15 mg BID", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "CP-690,550 30 mg BID", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This was a Phase 1 dose escalation study to evaluate the safety, tolerability and\n      pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients.  In\n      Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts\n      of subjects.  After Stage 1, one dose level was to be selected for dosing in an expanded\n      cohort in Stage 2."
        }, 
        "brief_title": "A Study Of CP-690,550 In Stable Kidney Transplant Patients", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                            "title": "Placebo, Stage 1"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 5 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 15 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "B4", 
                            "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                            "title": "CP-690,550 30 mg, Stage 1 And 2"
                        }, 
                        {
                            "@group_id": "B5", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "6"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "6"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "6"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@value": "10"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@value": "28"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "15.0", 
                                                "@value": "54.5"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "15.5", 
                                                "@value": "53.0"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "17.8", 
                                                "@value": "46.0"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@spread": "14.3", 
                                                "@value": "54.2"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@spread": "15.0", 
                                                "@value": "52.3"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "1"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "3"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "8"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "4"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "5"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "3"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "8"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "20"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "75.3", 
                                                        "@value": "183"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "182", 
                                                        "@value": "754"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "266", 
                                                        "@value": "1200"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For CP-690,550", 
                                    "units": "nanogram*hour per milliliter (ng*hr/mL)"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1", 
                        "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) at steady state.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "9"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "175", 
                                                        "@value": "319"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "241", 
                                                        "@value": "1300"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "311", 
                                                        "@value": "1560"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) at steady state.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) at Steady State For CP-690,550", 
                                    "units": "ng*hr/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29", 
                        "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) at Steady State For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Area under the plasma concentration time-curve from zero to 12 hour concentration [AUC(0-12)] at steady state.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "9"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "132", 
                                                        "@value": "273"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "150", 
                                                        "@value": "1090"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "253", 
                                                        "@value": "1420"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Area under the plasma concentration time-curve from zero to 12 hour concentration [AUC(0-12)] at steady state.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Curve From Time Zero to 12 Hour Concentration [AUC(0-12)] at Steady State For CP-690,550", 
                                    "units": "ng*hr/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 29", 
                        "title": "Area Under the Curve From Time Zero to 12 Hour Concentration [AUC(0-12)] at Steady State For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "14.9", 
                                                        "@value": "41.0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "34.5", 
                                                        "@value": "140"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "113", 
                                                        "@value": "325"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximum Observed Plasma Concentration (Cmax) For CP-690,550", 
                                    "units": "nanogram per milliliter (ng/mL)"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1", 
                        "title": "Maximum Observed Plasma Concentration (Cmax) For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "9"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "15.2", 
                                                        "@value": "52.2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "39.4", 
                                                        "@value": "220"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "46.3", 
                                                        "@value": "351"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximum Observed Plasma Concentration (Cmax) at Steady State For CP-690,550", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29", 
                        "title": "Maximum Observed Plasma Concentration (Cmax) at Steady State For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "2.00", 
                                                        "@value": "0.75"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "2.00", 
                                                        "@value": "1.50"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "2.00", 
                                                        "@value": "0.50"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) For CP-690,550", 
                                    "units": "hours"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1", 
                        "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "9"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "2.00", 
                                                        "@value": "0.75"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "1.00", 
                                                        "@value": "0.50"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "1.00", 
                                                        "@value": "0.50"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State For CP-690,550", 
                                    "units": "hours"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29", 
                        "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Rac obtained from AUC(0-12) (Day 29) divided by AUC(0-12) (Day 1).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "7"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.467", 
                                                        "@value": "1.48"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "0.245", 
                                                        "@value": "1.39"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "0.182", 
                                                        "@value": "1.22"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Rac obtained from AUC(0-12) (Day 29) divided by AUC(0-12) (Day 1).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Accumulation Ratio (Rac) For CP-690,550", 
                                    "units": "ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1 and 29", 
                        "title": "Accumulation Ratio (Rac) For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.869", 
                                                        "@value": "3.36"
                                                    }, 
                                                    {
                                                        "#text": "Data was not analyzed because there were not enough participants to perform a meaningful analysis.", 
                                                        "@group_id": "O2", 
                                                        "@spread": "NA", 
                                                        "@value": "NA"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "0.620", 
                                                        "@value": "2.94"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Plasma Decay Half-Life (t1/2) For CP-690,550", 
                                    "units": "hours"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1", 
                        "title": "Plasma Decay Half-Life (t1/2) For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half at steady state.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "4"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.00", 
                                                        "@value": "5.18"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "1.12", 
                                                        "@value": "5.15"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "0.201", 
                                                        "@value": "3.71"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half at steady state.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Plasma Decay Half-Life (t1/2) at Steady State For CP-690,550", 
                                    "units": "hours"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29", 
                        "title": "Plasma Decay Half-Life (t1/2) at Steady State For CP-690,550", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. The baseline for MPA trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "10"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.23", 
                                                        "@value": "2.73"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "1.80", 
                                                        "@value": "2.18"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "1.13", 
                                                        "@value": "1.84"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "1.80", 
                                                        "@value": "2.43"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. The baseline for MPA trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Baseline", 
                                    "units": "Milligram per Liter (mg/L)"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment.", 
                        "safety_issue": "No", 
                        "time_frame": "Screening, 0 hour (pre-dose) on Day 1", 
                        "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Baseline", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "10"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.77", 
                                                        "@value": "3.25"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "2.01", 
                                                        "@value": "2.11"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "0.48", 
                                                        "@value": "1.29"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "1.62", 
                                                        "@value": "2.56"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 8", 
                                    "units": "mg/L"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 8", 
                        "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 8", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "10"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.75", 
                                                        "@value": "3.15"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "2.21", 
                                                        "@value": "2.36"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "0.63", 
                                                        "@value": "1.48"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "1.52", 
                                                        "@value": "2.74"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 15", 
                                    "units": "mg/L"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 15", 
                        "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 15", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "10"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.77", 
                                                        "@value": "2.61"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "2.00", 
                                                        "@value": "2.68"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "3.88", 
                                                        "@value": "4.30"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "1.71", 
                                                        "@value": "3.24"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 29", 
                                    "units": "mg/L"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 29", 
                        "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 29", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                                    "title": "CP-690,550 30 mg, Stage 1 And 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "6"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "10"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.56", 
                                                        "@value": "2.60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "2.75", 
                                                        "@value": "2.89"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "1.10", 
                                                        "@value": "1.75"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "1.87", 
                                                        "@value": "2.67"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 57", 
                                    "units": "mg/L"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 57", 
                        "title": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 57", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The baseline for CsA trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "#text": "Standard deviation was not estimable since only 1 participant was evaluable.", 
                                                        "@group_id": "O1", 
                                                        "@spread": "NA", 
                                                        "@value": "249.50"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "41.99", 
                                                        "@value": "81.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "51.11", 
                                                        "@value": "173.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "The baseline for CsA trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Cyclosporine (CsA) Plasma Trough Concentration at Baseline", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "Screening, 0 hour (pre-dose) on Day 1", 
                        "title": "Cyclosporine (CsA) Plasma Trough Concentration at Baseline", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "4"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "#text": "Standard deviation was not estimable since only 1 participant was evaluable.", 
                                                        "@group_id": "O1", 
                                                        "@spread": "NA", 
                                                        "@value": "137.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "47.28", 
                                                        "@value": "77.25"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "17.78", 
                                                        "@value": "134.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 8", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 8", 
                        "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 8", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "#text": "Standard deviation was not estimable since only 1 participant was evaluable.", 
                                                        "@group_id": "O1", 
                                                        "@spread": "NA", 
                                                        "@value": "207.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "43.71", 
                                                        "@value": "86.60"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "24.58", 
                                                        "@value": "160.33"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 15", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 15", 
                        "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 15", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "#text": "Standard deviation was not estimable since only 1 participant was evaluable.", 
                                                        "@group_id": "O1", 
                                                        "@spread": "NA", 
                                                        "@value": "226.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "53.43", 
                                                        "@value": "96.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "22.34", 
                                                        "@value": "125.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 29", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 29", 
                        "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 29", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 5 mg, Stage 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "#text": "Standard deviation was not estimable since only 1 participant was evaluable.", 
                                                        "@group_id": "O1", 
                                                        "@spread": "NA", 
                                                        "@value": "292.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "72.71", 
                                                        "@value": "91.20"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "43.28", 
                                                        "@value": "152.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 57", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 57", 
                        "title": "Cyclosporine (CsA) Plasma Trough Concentration at Day 57", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The baseline for TAC trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.47", 
                                                        "@value": "6.75"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "1.76", 
                                                        "@value": "7.17"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "The baseline for TAC trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Tacrolimus (TAC) Plasma Trough Concentration at Baseline", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "Screening, 0 hour (pre-dose) on Day 1", 
                        "title": "Tacrolimus (TAC) Plasma Trough Concentration at Baseline", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.12", 
                                                        "@value": "7.50"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "1.00", 
                                                        "@value": "8.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 8", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 8", 
                        "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 8", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.83", 
                                                        "@value": "8.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "2.08", 
                                                        "@value": "6.67"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 15", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 15", 
                        "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 15", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.83", 
                                                        "@value": "7.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "4.51", 
                                                        "@value": "12.67"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 29", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 29", 
                        "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 29", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "Placebo, Stage 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                                    "title": "CP-690,550 15 mg, Stage 1"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.41", 
                                                        "@value": "5.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "0.58", 
                                                        "@value": "6.33"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 57", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Analysis population included all randomized participants who received at least 1 dose of study treatment. Here \"N\" (Number of Participants Analyzed) signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (pre-dose) on Day 57", 
                        "title": "Tacrolimus (TAC) Plasma Trough Concentration at Day 57", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (mycophenolate mofetil [MMF] with or without calcineurin inhibitor [cyclosporine {CsA} or tacrolimus {TAC}]) as per local clinical practice in Stage 1.", 
                            "title": "Placebo, Stage 1"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 5 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "P3", 
                            "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 15 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "P4", 
                            "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 30 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "P5", 
                            "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 2.", 
                            "title": "CP-690,550 30 mg, Stage 2"
                        }
                    ]
                }, 
                "period_list": {
                    "period": [
                        {
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P5"
                                                }
                                            ]
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "6", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P5"
                                                }
                                            ]
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P5"
                                                }
                                            ]
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Stage 1"
                        }, 
                        {
                            "drop_withdraw_reason_list": {
                                "drop_withdraw_reason": {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P3"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P4"
                                            }, 
                                            {
                                                "@count": "1", 
                                                "@group_id": "P5"
                                            }
                                        ]
                                    }, 
                                    "title": "Adverse Event"
                                }
                            }, 
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "4", 
                                                    "@group_id": "P5"
                                                }
                                            ]
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "3", 
                                                    "@group_id": "P5"
                                                }
                                            ]
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "1", 
                                                    "@group_id": "P5"
                                                }
                                            ]
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Stage 2"
                        }
                    ]
                }
            }, 
            "point_of_contact": {
                "email": "ClinicalTrials.gov_Inquiries@pfizer.com", 
                "name_or_title": "Pfizer ClinicalTrials.gov Call Center", 
                "organization": "Pfizer, Inc.", 
                "phone": "1-800-718-1021"
            }, 
            "reported_events": {
                "desc": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.", 
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Placebo matched to CP-690,550 tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) with or without calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                            "title": "Placebo, Stage 1"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "CP-690,550 5 milligram (mg) tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 5 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "E3", 
                            "description": "CP-690,550 15 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF), calcineurin inhibitor (CsA or TAC) as per local clinical practice in Stage 1.", 
                            "title": "CP-690,550 15 mg, Stage 1"
                        }, 
                        {
                            "@group_id": "E4", 
                            "description": "CP-690,550 30 mg tablet orally twice daily up to Day 28 followed by single oral dose on Day 29 in stable renal transplant recipients, receiving maintenance immunosuppression therapy (MMF) as per local clinical practice in Stage 1 and 2.", 
                            "title": "CP-690,550 30 mg, Stage 1 And 2"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Anaemia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Leukocytosis"
                                        }
                                    ]
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Vertigo"
                                    }
                                }, 
                                "title": "Ear and labyrinth disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Conjunctival haemorrhage"
                                    }
                                }, 
                                "title": "Eye disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Abdominal pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Abdominal pain lower"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Diarrhoea"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Dyspepsia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Eructation"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Gastrooesophageal reflux disease"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Gingival hyperplasia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Vomiting"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Catheter site haemorrhage"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Fatigue"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Malaise"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Bronchitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Cytomegalovirus viraemia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Gastroenteritis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Herpes simplex"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Laryngitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Nasopharyngitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Onychomycosis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Pharyngitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Pneumonia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Sinusitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Tinea versicolour"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Tonsillitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Upper respiratory tract infection"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Urinary tract infection"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Viral infection"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Viral upper respiratory tract infection"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Liver function test abnormal"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Reticulocyte count decreased"
                                        }
                                    ]
                                }, 
                                "title": "Investigations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Dehydration"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Hypokalaemia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Increased appetite"
                                        }
                                    ]
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Arthralgia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Back pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Chest wall pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Neck pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Pain in extremity"
                                        }
                                    ]
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Abnormal dreams"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Anxiety"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Insomnia"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Sleep disorder"
                                        }
                                    ]
                                }, 
                                "title": "Psychiatric disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Haematuria"
                                    }
                                }, 
                                "title": "Renal and urinary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Cough"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Nasal congestion"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Pharyngolaryngeal pain"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Hypertension"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 8.0", 
                    "frequency_threshold": "0"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Gastroenteritis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Urinary tract infection"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "6"
                                                }, 
                                                {
                                                    "@group_id": "E4", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "10"
                                                }
                                            ], 
                                            "sub_title": "Viral infection"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Blood creatinine increased"
                                    }
                                }, 
                                "title": "Investigations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "6"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "10"
                                            }
                                        ], 
                                        "sub_title": "Dehydration"
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 8.0"
                }
            }
        }, 
        "completion_date": {
            "#text": "April 2005", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Transplant", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medically stable kidney transplant patients 6 or more months after transplantation.\n\n          -  Subjects must be on mycophenolate mofetil 1-2 gm daily\n\n          -  In Cohort 3 (and 4, if conducted) in Stage 1 and the expanded cohort in Stage 2,\n             subjects must be on a calcineurin inhibitor-free regimen.\n\n        Exclusion Criteria:\n\n          -  Any rejection episodes in the preceding 3 months.\n\n          -  Treated with Thymoglobulin or OKT3 for acute rejection in the past 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "firstreceived_results_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710033", 
            "org_study_id": "A3921007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tables twice daily (BID) for 28 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CP-690,550 5 mg BID", 
                "description": "CP-690,550 5 mg BID for 28 days", 
                "intervention_name": "CP-690,550 5 mg BID", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CP-690,550 15 mg BID", 
                "description": "CP-690,550 15 mg BID for 28 days", 
                "intervention_name": "CP-690,550 15 mg BID", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CP-690,550 30 mg BID", 
                "description": "CP-690,550 30 mg BID for 28 days", 
                "intervention_name": "CP-690,550 30 mg BID", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "CP-690,550", 
            "kidney transplant"
        ], 
        "lastchanged_date": "November 26, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921007&StudyName=A%20Study%20Of%20CP-690%2C550%20In%20Stable%20Kidney%20Transplant%20Patients"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35249"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-6862"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35249-6860"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90057"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110-1093"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110-1092"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Livingston", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07039"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Unknown", 
                        "country": "Netherlands", 
                        "state": "Rotterdam"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) at steady state.", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) at Steady State For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to 12 hour concentration [AUC(0-12)] at steady state.", 
                "measure": "Area Under the Curve From Time Zero to 12 Hour Concentration [AUC(0-12)] at Steady State For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 29"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) at Steady State For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29"
            }, 
            {
                "description": "Rac obtained from AUC(0-12) (Day 29) divided by AUC(0-12) (Day 1).", 
                "measure": "Accumulation Ratio (Rac) For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1 and 29"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2) For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12 hours post-dose on Day 1"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half at steady state.", 
                "measure": "Plasma Decay Half-Life (t1/2) at Steady State For CP-690,550", 
                "safety_issue": "No", 
                "time_frame": "0 (pre-dose), 0.5, 1, 2, 4, 8, 10, 12, 24 hours post-dose on Day 29"
            }, 
            {
                "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. The baseline for MPA trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                "measure": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Baseline", 
                "safety_issue": "No", 
                "time_frame": "Screening, 0 hour (pre-dose) on Day 1"
            }, 
            {
                "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                "measure": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 8", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 8"
            }, 
            {
                "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                "measure": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 15", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 15"
            }, 
            {
                "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                "measure": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 29", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 29"
            }, 
            {
                "description": "Pro-drug MMF was metabolically converted to active form MPA in the liver. MPA levels were assessed at different visits to assess change in MPA trough levels due to CP-690,550 exposure.", 
                "measure": "Mycophenolic Acid (MPA) Plasma Trough Concentration at Day 57", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 57"
            }, 
            {
                "description": "The baseline for CsA trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                "measure": "Cyclosporine (CsA) Plasma Trough Concentration at Baseline", 
                "safety_issue": "No", 
                "time_frame": "Screening, 0 hour (pre-dose) on Day 1"
            }, 
            {
                "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                "measure": "Cyclosporine (CsA) Plasma Trough Concentration at Day 8", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 8"
            }, 
            {
                "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                "measure": "Cyclosporine (CsA) Plasma Trough Concentration at Day 15", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 15"
            }, 
            {
                "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                "measure": "Cyclosporine (CsA) Plasma Trough Concentration at Day 29", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 29"
            }, 
            {
                "description": "CsA levels were assessed at different visits to assess change in CsA trough levels due to CP-690,550 exposure.", 
                "measure": "Cyclosporine (CsA) Plasma Trough Concentration at Day 57", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 57"
            }, 
            {
                "description": "The baseline for TAC trough concentrations was defined as the average of the values obtained at Screening and on Day 1 (pre-dose). TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                "measure": "Tacrolimus (TAC) Plasma Trough Concentration at Baseline", 
                "safety_issue": "No", 
                "time_frame": "Screening, 0 hour (pre-dose) on Day 1"
            }, 
            {
                "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                "measure": "Tacrolimus (TAC) Plasma Trough Concentration at Day 8", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 8"
            }, 
            {
                "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                "measure": "Tacrolimus (TAC) Plasma Trough Concentration at Day 15", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 15"
            }, 
            {
                "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                "measure": "Tacrolimus (TAC) Plasma Trough Concentration at Day 29", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 29"
            }, 
            {
                "description": "TAC levels were assessed at different visits to assess change in TAC trough levels due to CP-690,550 exposure.", 
                "measure": "Tacrolimus (TAC) Plasma Trough Concentration at Day 57", 
                "safety_issue": "No", 
                "time_frame": "0 hour (pre-dose) on Day 57"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710033"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}